Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

Conditions

• Hodgkin Lymphoma in Remission
• Leukemia in Remission
• Lymphoblastic Lymphoma
• Osteosarcoma
• Recurrent Leukemia
• Recurrent Lymphoma
• Recurrent Malignant Neoplasm

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Assessment of Therapy Complications — OTHER
  Ancillary studies
• Laboratory Biomarker Analysis — OTHER
  Correlative studies
• Quality-of-Life Assessment — OTHER
  Ancillary studies
• Questionnaire Administration — OTHER
  Ancillary studies

Study Details

This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment.

Key Dates

Start date

Mar 5, 2014

Status verified

May 2026

Primary completion

Dec 31, 2022

Completion

Dec 31, 2026

Study Design

Enrollment

420 participants (estimated)

Arms

• Arm: Ancillary-Correlative (laboratory biomarker analysis)
  Patients complete a diagnostic symptom checklist, undergo a physical exam, echocardiogram, collection of serum for biomarker testing, and a 6 minute walk test, and complete quality of life, family history, physical activity, and smoking questionnaires.

Primary Outcome Measure

Left ventricular function and measures of pathologic remodeling (i.e., thickness-to-dimension ratio) assessed using standard 2-dimensional, M-mode, and Doppler echocardiogram [ Time Frame: Baseline ]

Locations (69)

Find similar trials in Birmingham, AL

Related Studies

• Clinical Orthopaedic Data Bank (Acute and Chronic)
  Recruiting · University of Florida · Gainesville, Florida
• Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
  PHASE1 · Recruiting · University of Wisconsin, Madison · Madison, Wisconsin
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
  PHASE2 · Recruiting · Mayo Clinic · Mankato, Minnesota
• Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
  Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey